Lucentis Effective for Proliferative Diabetic Retinopathy
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.
Language
English
Source: News from NEI - Category: Opthalmology Authors: Jason Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Health | Laser Therapy | Lucentis | National Institutes of Health (NIH) | Opthalmology | Ranibizumab Injection